Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356778 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL581064 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL514303 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL5651324 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2285351 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2305639 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL3857734 | 0.98 | CES1 (0.32) | CES1 | |
| SCHEMBL290664 | 0.92 | — | — | |
| SCHEMBL15792000 | 0.80 | CES1 (0.35) | CES1 | |
| SCHEMBL8000974 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | CES1 40/4885 |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | BDNF, NTRK2, NGF | CES1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.